Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
Hereditary spastic paraplegia type 4 Indication Strategy Report 2026: SPAST, Trials and Deals
30 July 2026
2026 Hereditary spastic paraplegia type 4 indication strategy covering epidemiology, SPAST biology, active trials, transactions, unmet need, competition and…
Latest Hotspot
8 min read
Hereditary spastic paraplegia type 15 Indication Strategy Report 2026: ZFYVE26, Trials and Deals
30 July 2026
2026 Hereditary spastic paraplegia type 15 indication strategy covering epidemiology, ZFYVE26 biology, active trials, transactions, unmet need, competition and…
Latest Hotspot
8 min read
Hereditary spastic paraplegia type 50 Indication Strategy Report 2026: AP4M1, Trials and Deals
30 July 2026
2026 Hereditary spastic paraplegia type 50 indication strategy covering epidemiology, AP4M1 biology, active trials, transactions, unmet need, competition and…
Latest Hotspot
8 min read
Hereditary spastic paraplegia type 11 Indication Strategy Report 2026: SPG11, Trials and Deals
30 July 2026
2026 Hereditary spastic paraplegia type 11 indication strategy covering epidemiology, SPG11 biology, active trials, transactions, unmet need, competition and…
Latest Hotspot
8 min read
Hereditary spastic paraplegia type 7 Indication Strategy Report 2026: SPG7, Trials and Deals
30 July 2026
2026 Hereditary spastic paraplegia type 7 indication strategy covering epidemiology, SPG7 biology, active trials, transactions, unmet need, competition and…
Latest Hotspot
8 min read
Fast-channel congenital myasthenic syndrome Indication Strategy Report 2026: CHRNE, Trials and Deals
30 July 2026
2026 Fast-channel congenital myasthenic syndrome indication strategy covering epidemiology, CHRNE biology, active trials, transactions, unmet need, competition…
Latest Hotspot
8 min read
Congenital myasthenic syndrome Indication Strategy Report 2026: CHRNE, Trials and Deals
30 July 2026
2026 Congenital myasthenic syndrome indication strategy covering epidemiology, CHRNE biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Morvan syndrome Indication Strategy Report 2026: CASPR2, Trials and Deals
30 July 2026
2026 Morvan syndrome indication strategy covering epidemiology, CASPR2 biology, active trials, transactions, unmet need, competition and market attractiveness.
Latest Hotspot
8 min read
MUSK myasthenia gravis Indication Strategy Report 2026: MUSK, Trials and Deals
30 July 2026
2026 MUSK myasthenia gravis indication strategy covering epidemiology, MUSK biology, active trials, transactions, unmet need, competition and market attractiveness.
Latest Hotspot
8 min read
Isaacs syndrome Indication Strategy Report 2026: VGKC, Trials and Deals
30 July 2026
2026 Isaacs syndrome indication strategy covering epidemiology, VGKC biology, active trials, transactions, unmet need, competition and market attractiveness.
Latest Hotspot
8 min read
Sensory neuronopathy Indication Strategy Report 2026: CD20, Trials and Deals
30 July 2026
2026 Sensory neuronopathy indication strategy covering epidemiology, CD20 biology, active trials, transactions, unmet need, competition and market attractiveness.
Latest Hotspot
8 min read
Paraneoplastic cerebellar degeneration Indication Strategy Report 2026: CD20, Trials and Deals
30 July 2026
2026 Paraneoplastic cerebellar degeneration indication strategy covering epidemiology, CD20 biology, active trials, transactions, unmet need, competition and…